The Cardiovascular Disorders Market Outlook to 2012

Table of Contents

Executive Summary

• Patient potential
• Global market analysis
• Pipeline analysis
• Competitive landscape

Chapter 1 Epidemiology of Cardiovascular

• disorders
• Summary
• Introduction
• Cardiovascular Risk Factors
• Hypertension
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Dyslipidemia
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Diabetes
• Overview
• Diagnosis, treatment and management
• Epidemiology
• Forecast epidemiology
• Cardiovascular disease
• Overview
• Epidemiology
• Acute thrombotic events
  • Acute coronary syndromes
  • Venous thromboembolism
  • Stroke
• Cardiovascular procedures

Chapter 2 Global market analysis

• Summary
• Introduction
• Market analysis by country
• Licensing trends
• Market analysis by drug class
• Leading brands dynamics
• Key events in the cardiovascular market
• Use of ACE inhibitors by pregnant women linked to associated birth defects
• risks
• Arrival of generic competition to key brands
• Positive clinical trials further boost sales generation for major brands Diovan
• and Lipitor
• Anti-hypertensives
• Market analysis by drug class
• Leading brands in the Anti-hypertensives market
• ACE Inhibitors (ACEIs)
  • Market dynamics
  • Key brands analysis
• Beta Blockers
  • Market dynamics
• Diuretics
  • Market dynamics
  • Key brands analysis
• Calcium Channel Blockers (CCBs)
  • Market dynamics
  • Key brands analysis
• Angiotensin Receptor Blockers (ARBs)
  • Market dynamics
  • Key brands analysis
• Sales forecasts to 2012 for Anti Hypertensives
• Anti-dyslipidemics
• Market analysis by drug class
• Leading brands in the Anti-dyslipidemics market
• Market analysis by drug class
  • Statins
  • Fibrates
  • Non-statin products
  • Other anti-dyslipidemics
• Sales forecasts to 2012 for Anti dyslipidemics
• Anti-Thrombotics
• Market analysis by drug class
• Leading brand dynamics
• Anti-platelets
  • Market dynamics
  • Key brands analysis
• Heparins
  • Market dynamics
  • Key brands analysis
• Vit K antagonists
  • Fibrinolytics
• Sales forecasts to 2012 for Anti thrombotics
• Cardiac Therapies
• Market analysis by drug class
• Leading brands of Cardiac Therapies
  • Other cardiac therapies
  • Nitrites and nitrates
  • Leading-brand dynamics
  • Anti-arrhythmics
• Sales forecasts to 2012 for Cardiac Therapies 2007-12
• Total CVD market sales forecasts to 2012

Chapter 3 Pipeline analysis

• Summary
• Introduction
• Key trends in cardiovascular R&D
• Combination drugs
• New class of drugs
• New mechanism of action
• New drug delivery formulations
• The pipeline for cardiovascular disorders
• Leading drugs in development
• Profiles of key pipeline products
• Phase II compounds
  • ARC 1779
  • KB 2115
• Phase III compounds
  • Cleviprex (clevidipine)
  • Stedicor (azimilide)
  • BAY-597939 (rivaroxaban)
• Drugs pending approval
  • Thelin (sitaxsentan)
  • Simcor (niacin and simvastatin)
• Recently marketed drugs
  • Azor (amlodipine/olmesartan)
  • Tekturna/Rasilez (aliskiren)
  • Exforge (amlodipine/valsartan)
  • Ranexa (ranolazine)

Chapter 4 Competitive landscape

• Summary
• Company market shares
• Pfizer
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Merck
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Novartis
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D compounds
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Sanofi Aventis
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• AstraZeneca
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Bristol-Myers Squibb
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Daiichi Sankyo
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Servier
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth
• Glaxo SmithKline
• Overview
• Sales focus by drug class
• Marketed product portfolio
• R&D pipeline analysis
• Strategic and growth analysis
  • Drivers of growth
  • Resistors of growth

Chapter 5 Appendix

• ATC codes used in analysis
• Licensing status as per IMS Health
• Original brand
• Other brand
• Licensed brand
• Not-coded product
• Unbranded/ generic product
• Diagnosis profile analysis
• Index

List of Figures

• Figure 1.1: Relationship between Cardiovascular Risk Factors and Diseases
• Figure 1.2: Typical treatment patterns in the treatment of hypertension
• Figure 1.3: Typical treatment patterns in the treatment of dyslipidemia
• Figure 1.4: Typical treatment patterns in the treatment of diabetes
• Figure 1.5: Typical treatment patterns in the treatment of acute thrombotic events
• Figure 2.6: Global cardiovascular market share by geography, 2007
• Figure 2.7: Sales of types of cardiovascular brands, 2006-07
• Figure 2.8: Competitive dynamics of the global CVD market by drug class, 2007
• Figure 2.9: Forecast dynamics of the leading 10 cardiovascular brands, 2006-07
• Figure 2.10: Competitive dynamics in the global anti-hypertensives market by drug class, 2006-07
• Figure 2.11: Market movement for anti-hypertensive brands, 2006
• Figure 2.12: Diagnosis profile of ACE inhibitor sales, 2006
• Figure 2.13: Diagnosis profile of Beta Blockers, 2006
• Figure 2.14: Diagnosis profile of Calcium channel blockers, 2006
• Figure 2.15: Diagnosis profile of ARBs, 2006
• Figure 2.16: Diagnosis profile of Anti-dyslipidemics, 2006
• Figure 2.17: Competitive dynamics in the global anti-thrombotics market by class, 2006-07
• Figure 2.18: Market movement for anti-thrombotic brands, 2006
• Figure 2.19: Diagnosis profile of anti-platelets, 2006
• Figure 2.20: Diagnosis profile of Heparins, 2006
• Figure 2.21: Diagnosis profile of cardiac therapies, 2006
• Figure 2.22: Competitive dynamics in the global cardiac therapies market by class, 2006-07
• Figure 3.23: Prevailing R&D approaches for cardiovascular diseases, 2006
• Figure 3.24: The CVD pipeline by indication and stage of development, 2006
• Figure 3.25: Leading recently launched and late-stage cardiovascular products, 2007
• Figure 4.26: Competitive dynamics of the leading players in the global cardiovascular market, 2007
• Figure 4.27: Pfizer' s franchise sales by drug class, 2006
• Figure 4.28: Merck' s franchise sales by drug class, 2006
• Figure 4.29: Novartis' franchise sales by drug class, 2006
• Figure 4.30: Sanofi Aventis' franchise sales by drug class, 2006
• Figure 4.31: AstraZeneca' s franchise sales by drug class, 2006
• Figure 4.32: BMS' franchise sales by drug class, 2006
• Figure 4.33: Daiichi' s franchise sales by drug class, 2006
• Figure 4.34: Servier' s franchise sales by drug class, 2006
• Figure 4.35: GSK' s franchise sales by drug class, 2006

List of Tables

• Table 1.1: Estimated prevalence of CVD across the seven major pharmaceutical markets, 2006
• Table 1.2: Proposed revision definition of hypertension, 2005
• Table 1.3: Estimated prevalence of hypertension in across seven major markets, 2006
• Table 1.4: Forecast epidemiology of hypertension across the seven major markets, 2006-12
• Table 1.5: Clinical guidelines for adult patients at borderline and high risk of cardiovascular disease by serum levels of lipids
• Table 1.6: Estimated prevalence of dyslipidemia across seven major markets, 2006
• Table 1.7: Forecast epidemiology of dyslipidemia across the seven major markets, 2006-12
• Table 1.8: Various pharmacological therapies for the treatment and management of diabetes
• Table 1.9: Estimated prevalence of diabetes in the seven major markets, 2006
• Table 1.10: Forecast epidemiology of diabetes across the seven major markets, 2006-12
• Table 1.11: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2006
• Table 1.12: Estimated incidence of ACS in the seven major markets, 2006
• Table 1.13: Estimated incidence of VTE in the seven major markets, 2006
• Table 1.14: Prevalence of stroke in the seven major markets, 2006
• Table 1.15: Estimated incidence of cardiovascular procedures in the seven major markets, 2006
• Table 2.16: Breakdown of the global CVD market by drug class, 2003-07
• Table 2.17: Leading brands in the global cardiovascular market, 2006-07
• Table 2.18: Breakdown of the global anti-hypertensive market by drug class, 2003-07
• Table 2.19: Leading anti-hypertensive brands, 2006-07
• Table 2.20: Leading ACE inhibitor brands, 2006-07
• Table 2.21: Leading Beta blocker brands, 2006-07
• Table 2.22: Leading diuretics brands, 2006-07
• Table 2.23: Leading CCBs brands in the global CVD market, 2006-07
• Table 2.24: Leading ARBs brands in the global CVD market, 2006-07
• Table 2.25: Anti-hypertensives sales forecast for ARBs, Beta-blockers & CCBs, 2007-12
• Table 2.26: Anti-hypertensives sales forecast for ACE inhibitors, Diuretics & Pipeline products, 2007-12
• Table 2.27: Breakdown of the global anti-dyslipidemic market by drug class, 2003-07
• Table 2.28: Leading anti-dyslipidemia products in the global CVD market, 2006-07
• Table 2.29: Anti-dyslipidemics sales forecasts, 2007-12
• Table 2.30: Breakdown of the global anti-thrombotics market by drug class, 2003-07
• Table 2.31: Leading anti-thrombotics products in the global CVD market, 2006-07
• Table 2.32: Leading anti-platelet brands in the global CVD market, 2006-07
• Table 2.33: Leading heparin brands in the global CVD market, 2006-07
• Table 2.34: Anti-thrombotics sales forecasts, 2007-12
• Table 2.35: Breakdown of the global anti-thrombotics market by drug class, 2003-07
• Table 2.36: Leading cardiac therapy products in the global CVD market, 2006-07
• Table 2.37: Cardiac therapies' sales forecasts, 2007-12
• Table 2.38: Cardiovacular market sales forecasts by drug class, 2006-12 ($m)
• Table 4.39: Leading players in the global cardiovascular disorders market, 2006-07
• Table 4.40: Pfizer' s CVD product portfolio, 2005-06
• Table 4.41: Pfizer' s cardiovascular product pipeline, 2006
• Table 4.42: Merck' s CVD product portfolio, 2005-06
• Table 4.43: Merck' s cardiovascular R&D product pipeline, 2006
• Table 4.44: Novartis' CVD product portfolio, 2005-06
• Table 4.45: Novartis' cardiovascular R&D product pipeline, 2006
• Table 4.46: Sanofi Aventis' CVD product portfolio, 2005-06
• Table 4.47: Sanofi Aventis' cardiovascular R&D product pipeline, 2006
• Table 4.48: AstraZeneca' s CVD product portfolio, 2005-06
• Table 4.49: AstraZeneca' s cardiovascular R&D product pipeline, 2006
• Table 4.50: BMS' s CVD product portfolio, 2005-06
• Table 4.51: BMS' cardiovascular R&D product pipeline, 2006
• Table 4.52: Daiichi' s CVD product portfolio, 2005-06
• Table 4.53: Daichii' s cardiovascular R&D product pipeline, 2006
• Table 4.54: Servier' s CVD product portfolio, 2005-06
• Table 4.55: GSK' s CVD product portfolio, 2005-06
• Table 4.56: GSK' s cardiovascular R&D product pipeline, 2006